Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
At Hospital/Institution:  Presbyterian - St. Luke's Medical Center
Keywords/Phrases:  leukemia
Results 1-25 of 924 for your search:
Start Over
SL-401 in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm or Acute Myeloid Leukemia
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: STML-401-0114, NCI-2014-01146, NCT02113982
Temozolomide and Vorinostat in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: HEMAML0017, NCI-2012-00229, 22794, NCT01550224
A First-in-Human Phase 1 and Expanded Cohort Study of EPZ-5676 in Advanced Hematologic Malignancies, Including Acute Leukemia With Rearrangement of the MLL Gene
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: EPZ-5676-12-001, NCI-2012-02880, NCT01684150
Azacitidine in Preventing Relapse in Patients with Acute Myelogenous Leukemia or Myelodysplastic Syndrome Previously Treated With Donor Stem Cell Transplant
Phase: Phase III
Type: Treatment
Age: 18 to 75
Trial IDs: 2008-0503, NCI-2012-01259, NCI-2009-01513, NCT00887068
Nilotinib and Binimetinib in Treating Patients with Refractory or Advanced Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Leukemia
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2014-0128, NCI-2015-00044, NCT02225574
Donor Stem Cell Transplant and Natural Killer Cells in Treating Patients With Advanced or Refractory Hematologic Malignancies
Phase: Phase I
Type: Treatment
Age: 18 to 65
Trial IDs: IUCRO-0179, NCI-2011-02350, NCT00569179
Donor Peripheral Blood Stem Cell Transplant in Treating Patients with Hematological Malignancies
Phase: Phase II
Type: Treatment
Age: 0 to 19
Trial IDs: 12-053, NCI-2012-00822, NCT01598025
Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 14 to 75
Trial IDs: 12-1191, NCI-2013-00782, NCT01839916
Bendamustine Hydrochloride, Clofarabine, and Etoposide in Treating Younger Patients with Relapsed or Refractory Hematologic Malignancies
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 21 and under
Trial IDs: BECHEM, NCI-2013-01148, TEVA ISS, NCT01900509
Cyclophosphamide, Fludarabine Phosphate, and Donor White Blood Cells Treating Patients With Hematologic Malignancies That Relapsed After a Previous Donor Stem Cell Transplant
Phase: Phase II
Type: Treatment
Age: 1 and over
Trial IDs: MT2003-15, NCI-2010-01695, 2004LS006, NCT00303693, NCT00167180
Sirolimus, Cyclosporine, and Mycophenolate Mofetil In Preventing Graft-Versus-Host Disease in Treating Patients with Hematologic Malignancies Undergoing Donor Peripheral Blood Stem Cell Transplant
Phase: Phase II
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: Not specified
Trial IDs: 2206.00, NCI-2010-02222, NCT01251575
Azacitidine in Treating Patients Undergoing Matched Unrelated Stem Cell Transplant
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 65
Trial IDs: 201303012, NCI-2012-03105, NCT01747499
Rasburicase or Allopurinol in Preventing Tumor Lysis Syndrome in Patients with Hematological Malignancies Undergoing Chemotherapy
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: Not specified
Trial IDs: 2010-0284, NCI-2012-01889, NCI-2010-02082, NCT01200485
CALIPSO: Calfactant for Acute Lung Injury in Pediatric Stem Cell Transplant and Oncology Patients
Phase: Phase III, Phase II
Type: Supportive care
Age: 18 months to 21 years
Trial IDs: #1R01FD003410-01, NCI-2014-01209, R01 FD003410-01-A1, NCT00999713
Cyclophosphamide in Preventing GVHD in Patients with Abnormal Kidney Function Undergoing Donor Stem Cell Transplant
Phase: No phase specified
Type: Natural history/Epidemiology, Supportive care
Age: 18 and over
Trial IDs: 14-273, NCI-2015-00266, NCT02360111
Low-Dose Chemotherapy, Low-Dose Total-Body Irradiation, and Anti-Thymocyte Globulin Followed By Donor Bone Marrow Transplant in Treating Patients With Hematologic Malignancy or Kidney Cancer
Phase: Phase II
Type: Treatment
Age: Under 70
Trial IDs: MT2001-10, NCI-2010-02155, 2001LS058, UMN-2001LS058, UMN-MT2001-10, NCT00303719
Bortezomib in Preventing Graft-Versus-Host Disease After Reduced-Intensity Donor Stem Cell Transplant in Patients With Hematologic Malignancies
Phase: Phase II
Type: Supportive care, Treatment
Age: 18 to 75
Trial IDs: 12-404, NCI-2013-00623, NCT01754389
Donor Umbilical Cord Blood Transplant in Treating Patients with Hematologic Cancer
Phase: Phase II
Type: Treatment
Age: Any age
Trial IDs: 2239.00, NCI-2009-01551, 2239, FHCRC-2239.00, 6722, FHCRC-IR-6722, NCT00723099
Safety Study of Anti-LAG-3 in CLL, HL, NHL and MM
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CA224-022, NCI-2014-01120, NCT02061761
Study of Biomarkers in DNA Samples From Patients With Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia
Phase: No phase specified
Type: Biomarker/Laboratory analysis
Age: Children and adults
Trial IDs: ABTR02B1, NCI-2009-00325, CDR0000271322, COG-ABTR02B1, NCT01005277
Selinexor in Treating Younger Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 months to 21 years
Trial IDs: 13-563, NCI-2014-00936, NCT02091245
Combination Chemotherapy in Treating Patients with Recurrent Acute Myeloid Leukemia or Recurrent Acute Lymphoblastic Leukemia
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 64
Trial IDs: 2012-1064, NCI-2013-00548, NCT01794702
Start Over